Antidiabetic Drug Market Research Report by Type (Alpha-glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, and Insulin), by Disease (Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2), by Patient - Global Forecast to 2025 - Cumulative Impact of COVID-19
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Antidiabetic Drug Market is expected to grow from USD 35,298.17 Million in 2020 to USD 56,146.71 Million by the end of 2025.
2. The Global Antidiabetic Drug Market is expected to grow from EUR 30,950.10 Million in 2020 to EUR 49,230.50 Million by the end of 2025.
3. The Global Antidiabetic Drug Market is expected to grow from GBP 27,514.71 Million in 2020 to GBP 43,766.02 Million by the end of 2025.
4. The Global Antidiabetic Drug Market is expected to grow from JPY 3,767,209.19 Million in 2020 to JPY 5,992,276.71 Million by the end of 2025.
5. The Global Antidiabetic Drug Market is expected to grow from AUD 51,257.63 Million in 2020 to AUD 81,532.49 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Antidiabetic Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the Antidiabetic Drug Market studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, Insulin, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) Inhibitors, Sulphonylureas, and Thiazolidinedione. The Insulin further studied across Intermediate-acting Insulin, Long-acting Analog, Premixed Insulin, Rapid-acting Analog, and Short-acting Analog.
Based on Disease, the Antidiabetic Drug Market studied across Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2.
Based on Patient, the Antidiabetic Drug Market studied across Adult, Geriatric, and Pediatric.
Based on Geography, the Antidiabetic Drug Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Antidiabetic Drug Market including Abbott Laboratories, Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, C.H. Boehringer Sohn AG & Co. KG, Cadila Pharmaceuticals Limited, Cipla, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals), Mankind Pharma Ltd, Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., TONGHUA DONGBAO PHARMACEUTICAL CO., LTD., and Wockhardt Limited.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Antidiabetic Drug Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Antidiabetic Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antidiabetic Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antidiabetic Drug Market?
4. What is the competitive strategic window for opportunities in the Global Antidiabetic Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Antidiabetic Drug Market?
6. What are the modes and strategic moves considered suitable for entering the Global Antidiabetic Drug Market?
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Antidiabetic Drug Market is expected to grow from USD 35,298.17 Million in 2020 to USD 56,146.71 Million by the end of 2025.
2. The Global Antidiabetic Drug Market is expected to grow from EUR 30,950.10 Million in 2020 to EUR 49,230.50 Million by the end of 2025.
3. The Global Antidiabetic Drug Market is expected to grow from GBP 27,514.71 Million in 2020 to GBP 43,766.02 Million by the end of 2025.
4. The Global Antidiabetic Drug Market is expected to grow from JPY 3,767,209.19 Million in 2020 to JPY 5,992,276.71 Million by the end of 2025.
5. The Global Antidiabetic Drug Market is expected to grow from AUD 51,257.63 Million in 2020 to AUD 81,532.49 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Antidiabetic Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the Antidiabetic Drug Market studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, Insulin, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) Inhibitors, Sulphonylureas, and Thiazolidinedione. The Insulin further studied across Intermediate-acting Insulin, Long-acting Analog, Premixed Insulin, Rapid-acting Analog, and Short-acting Analog.
Based on Disease, the Antidiabetic Drug Market studied across Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2.
Based on Patient, the Antidiabetic Drug Market studied across Adult, Geriatric, and Pediatric.
Based on Geography, the Antidiabetic Drug Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Antidiabetic Drug Market including Abbott Laboratories, Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, C.H. Boehringer Sohn AG & Co. KG, Cadila Pharmaceuticals Limited, Cipla, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals), Mankind Pharma Ltd, Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., TONGHUA DONGBAO PHARMACEUTICAL CO., LTD., and Wockhardt Limited.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Antidiabetic Drug Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Antidiabetic Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antidiabetic Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antidiabetic Drug Market?
4. What is the competitive strategic window for opportunities in the Global Antidiabetic Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Antidiabetic Drug Market?
6. What are the modes and strategic moves considered suitable for entering the Global Antidiabetic Drug Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Patient Outlook
3.4. Type Outlook
3.5. Disease Outlook
3.6. Geography Outlook
3.7. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Changing lifestyle of people and irregular dietary habits
5.1.1.2. Strong product pipeline of antidiabetics
5.1.1.3. Globally rising prevalence of diabetes and increasing obesity among people
5.1.1.4. Increasing consumer awareness level and improved technology
5.1.2. Restraints
5.1.2.1. Prohibitive cost of Insulin
5.1.3. Opportunities
5.1.3.1. Advancement in the healthcare and pharmaceutical sectors
5.1.3.2. Ongoing research and development
5.1.3.3. Governments and private companies to work together for the supply of inexpensive drugs
5.1.4. Challenges
5.1.4.1. Wide availability of antidiabetics drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL ANTIDIABETIC DRUG MARKET, BY TYPE
6.1. Introduction
6.2. Alpha-glucosidase Inhibitors
6.3. Biguanides
6.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
6.5. GLP-1 (Glucagon-like Peptide) Agonists
6.6. Insulin
6.6.1. Intermediate-acting Insulin
6.6.2. Long-acting Analog
6.6.3. Premixed Insulin
6.6.4. Rapid-acting Analog
6.6.5. Short-acting Analog
6.7. Meglitinides
6.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
6.9. Sulphonylureas
6.10. Thiazolidinedione
7. GLOBAL ANTIDIABETIC DRUG MARKET, BY DISEASE
7.1. Introduction
7.2. Diabetes Mellitus Type
7.3. Diabetes Mellitus Type
8. GLOBAL ANTIDIABETIC DRUG MARKET, BY PATIENT
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatric
9. AMERICAS ANTIDIABETIC DRUG MARKET
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. South Korea
10.10. Thailand
11. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. COMPETITIVE LANDSCAPE
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis
12.4. Competitor SWOT Analysis
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion
13. COMPANY USABILITY PROFILES
13.1. Abbott Laboratories
13.2. Aristo Pharmaceuticals Pvt. Ltd.
13.3. Astellas Pharma Inc.
13.4. AstraZeneca PLC
13.5. Biocon Limited
13.6. C.H. Boehringer Sohn AG & Co. KG
13.7. Cadila Pharmaceuticals Limited
13.8. Cipla, Inc.
13.9. Eli Lilly and Company
13.10. F. Hoffmann-La Roche Ltd.
13.11. GlaxoSmithKline PLC
13.12. Glenmark Pharmaceuticals Ltd.
13.13. Halozyme Therapeutics, Inc.
13.14. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
13.15. Mankind Pharma Ltd
13.16. Merck KGaA
13.17. Novo Nordisk A/S
13.18. Oramed Pharmaceuticals Inc.
13.19. Pfizer Inc.
13.20. PHC Corporation
13.21. Sanofi S.A.
13.22. Takeda Pharmaceutical Company Limited
13.23. Teva Pharmaceutical Industries Ltd.
13.24. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
13.25. Wockhardt Limited
14. APPENDIX
14.1. Discussion Guide
14.2. License & Pricing
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Patient Outlook
3.4. Type Outlook
3.5. Disease Outlook
3.6. Geography Outlook
3.7. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Changing lifestyle of people and irregular dietary habits
5.1.1.2. Strong product pipeline of antidiabetics
5.1.1.3. Globally rising prevalence of diabetes and increasing obesity among people
5.1.1.4. Increasing consumer awareness level and improved technology
5.1.2. Restraints
5.1.2.1. Prohibitive cost of Insulin
5.1.3. Opportunities
5.1.3.1. Advancement in the healthcare and pharmaceutical sectors
5.1.3.2. Ongoing research and development
5.1.3.3. Governments and private companies to work together for the supply of inexpensive drugs
5.1.4. Challenges
5.1.4.1. Wide availability of antidiabetics drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL ANTIDIABETIC DRUG MARKET, BY TYPE
6.1. Introduction
6.2. Alpha-glucosidase Inhibitors
6.3. Biguanides
6.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
6.5. GLP-1 (Glucagon-like Peptide) Agonists
6.6. Insulin
6.6.1. Intermediate-acting Insulin
6.6.2. Long-acting Analog
6.6.3. Premixed Insulin
6.6.4. Rapid-acting Analog
6.6.5. Short-acting Analog
6.7. Meglitinides
6.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
6.9. Sulphonylureas
6.10. Thiazolidinedione
7. GLOBAL ANTIDIABETIC DRUG MARKET, BY DISEASE
7.1. Introduction
7.2. Diabetes Mellitus Type
7.3. Diabetes Mellitus Type
8. GLOBAL ANTIDIABETIC DRUG MARKET, BY PATIENT
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatric
9. AMERICAS ANTIDIABETIC DRUG MARKET
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. South Korea
10.10. Thailand
11. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. COMPETITIVE LANDSCAPE
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis
12.4. Competitor SWOT Analysis
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion
13. COMPANY USABILITY PROFILES
13.1. Abbott Laboratories
13.2. Aristo Pharmaceuticals Pvt. Ltd.
13.3. Astellas Pharma Inc.
13.4. AstraZeneca PLC
13.5. Biocon Limited
13.6. C.H. Boehringer Sohn AG & Co. KG
13.7. Cadila Pharmaceuticals Limited
13.8. Cipla, Inc.
13.9. Eli Lilly and Company
13.10. F. Hoffmann-La Roche Ltd.
13.11. GlaxoSmithKline PLC
13.12. Glenmark Pharmaceuticals Ltd.
13.13. Halozyme Therapeutics, Inc.
13.14. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
13.15. Mankind Pharma Ltd
13.16. Merck KGaA
13.17. Novo Nordisk A/S
13.18. Oramed Pharmaceuticals Inc.
13.19. Pfizer Inc.
13.20. PHC Corporation
13.21. Sanofi S.A.
13.22. Takeda Pharmaceutical Company Limited
13.23. Teva Pharmaceutical Industries Ltd.
13.24. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
13.25. Wockhardt Limited
14. APPENDIX
14.1. Discussion Guide
14.2. License & Pricing
LIST OF TABLES
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 81. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 82. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 83. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 84. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 85. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 86. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 87. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 88. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 89. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 90. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 91. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 92. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 93. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 94. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 95. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 96. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 97. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 98. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 99. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 100. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 101. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 102. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 103. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 104. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 105. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 106. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 107. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 108. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 109. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 110. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 111. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 112. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 113. GLOBAL ANTIDIABETIC DRUG MARKET: SCORES
TABLE 114. GLOBAL ANTIDIABETIC DRUG MARKET: BUSINESS STRATEGY
TABLE 115. GLOBAL ANTIDIABETIC DRUG MARKET: PRODUCT SATISFACTION
TABLE 116. GLOBAL ANTIDIABETIC DRUG MARKET: RANKING
TABLE 117. GLOBAL ANTIDIABETIC DRUG MARKET: MERGER & ACQUISITION
TABLE 118. GLOBAL ANTIDIABETIC DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 119. GLOBAL ANTIDIABETIC DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 120. GLOBAL ANTIDIABETIC DRUG MARKET: INVESTMENT & FUNDING
TABLE 121. GLOBAL ANTIDIABETIC DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 122. GLOBAL ANTIDIABETIC DRUG MARKET: LICENSE & PRICING
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 81. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 82. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 83. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 84. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 85. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 86. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 87. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 88. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 89. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 90. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 91. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 92. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 93. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 94. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 95. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 96. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 97. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 98. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 99. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 100. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 101. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 102. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 103. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 104. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 105. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 106. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 107. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 108. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 109. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 110. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 111. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 112. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 113. GLOBAL ANTIDIABETIC DRUG MARKET: SCORES
TABLE 114. GLOBAL ANTIDIABETIC DRUG MARKET: BUSINESS STRATEGY
TABLE 115. GLOBAL ANTIDIABETIC DRUG MARKET: PRODUCT SATISFACTION
TABLE 116. GLOBAL ANTIDIABETIC DRUG MARKET: RANKING
TABLE 117. GLOBAL ANTIDIABETIC DRUG MARKET: MERGER & ACQUISITION
TABLE 118. GLOBAL ANTIDIABETIC DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 119. GLOBAL ANTIDIABETIC DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 120. GLOBAL ANTIDIABETIC DRUG MARKET: INVESTMENT & FUNDING
TABLE 121. GLOBAL ANTIDIABETIC DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 122. GLOBAL ANTIDIABETIC DRUG MARKET: LICENSE & PRICING
LIST OF FIGURES
FIGURE 1. GLOBAL ANTIDIABETIC DRUG MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL ANTIDIABETIC DRUG MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 (USD MILLION)
FIGURE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 (USD MILLION)
FIGURE 6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 (USD MILLION)
FIGURE 7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 12. GLOBAL ANTIDIABETIC DRUG MARKET: MARKET DYNAMICS
FIGURE 13. GLOBAL ANTIDIABETIC DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2025 (%)
FIGURE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2025 (USD MILLION)
FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2025
FIGURE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, 2020 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 25. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, 2020 VS 2025 (USD MILLION)
FIGURE 26. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, 2020 VS 2025 (USD MILLION)
FIGURE 30. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, 2020 VS 2025 (USD MILLION)
FIGURE 31. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2025 (%)
FIGURE 32. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2025 (USD MILLION)
FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2025
FIGURE 34. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, 2020 VS 2025 (USD MILLION)
FIGURE 35. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, 2020 VS 2025 (USD MILLION)
FIGURE 36. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2025 (%)
FIGURE 37. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2025 (USD MILLION)
FIGURE 38. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2025
FIGURE 39. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, 2020 VS 2025 (USD MILLION)
FIGURE 40. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, 2020 VS 2025 (USD MILLION)
FIGURE 41. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, 2020 VS 2025 (USD MILLION)
FIGURE 42. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 43. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 44. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 45. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 51. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 52. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 53. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 56. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 57. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 63. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 64. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 65. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 69. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 70. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 71. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 72. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 73. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 74. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 75. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 76. GLOBAL ANTIDIABETIC DRUG MARKET: 360IRESEARCH™ FPNV POSITIONING MATRIX
FIGURE 77. GLOBAL ANTIDIABETIC DRUG MARKET: 360IRESEARCH™ MARKET SHARE ANALYSIS
FIGURE 78. GLOBAL ANTIDIABETIC DRUG MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 79. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTIDIABETIC DRUG MARKET, BY TYPE
FIGURE 1. GLOBAL ANTIDIABETIC DRUG MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL ANTIDIABETIC DRUG MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 (USD MILLION)
FIGURE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 (USD MILLION)
FIGURE 6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 (USD MILLION)
FIGURE 7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 12. GLOBAL ANTIDIABETIC DRUG MARKET: MARKET DYNAMICS
FIGURE 13. GLOBAL ANTIDIABETIC DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2025 (%)
FIGURE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2025 (USD MILLION)
FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2025
FIGURE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, 2020 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, 2020 VS 2025 (USD MILLION)
FIGURE 25. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, 2020 VS 2025 (USD MILLION)
FIGURE 26. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, 2020 VS 2025 (USD MILLION)
FIGURE 30. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, 2020 VS 2025 (USD MILLION)
FIGURE 31. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2025 (%)
FIGURE 32. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2025 (USD MILLION)
FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2025
FIGURE 34. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, 2020 VS 2025 (USD MILLION)
FIGURE 35. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, 2020 VS 2025 (USD MILLION)
FIGURE 36. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2025 (%)
FIGURE 37. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2025 (USD MILLION)
FIGURE 38. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2025
FIGURE 39. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, 2020 VS 2025 (USD MILLION)
FIGURE 40. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, 2020 VS 2025 (USD MILLION)
FIGURE 41. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, 2020 VS 2025 (USD MILLION)
FIGURE 42. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 43. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 44. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 45. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 51. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 52. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 53. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 56. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 57. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 63. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 64. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 65. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 69. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 70. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 71. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 72. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 73. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 74. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 75. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 76. GLOBAL ANTIDIABETIC DRUG MARKET: 360IRESEARCH™ FPNV POSITIONING MATRIX
FIGURE 77. GLOBAL ANTIDIABETIC DRUG MARKET: 360IRESEARCH™ MARKET SHARE ANALYSIS
FIGURE 78. GLOBAL ANTIDIABETIC DRUG MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 79. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTIDIABETIC DRUG MARKET, BY TYPE
